Search

Global Health Watch: mRNA vax contracts cancelled, Gates Foundation commits to women’s health R&D, SA invests in research

This week the US administration cancelled $500 million in mRNA vaccine contracts while a Government Accountability Office investigation found the NIH grant freezes violated the law. The Gates Foundation committed $2.5 billion to women’s health R&D, and South Africa is investing to protect its national research capacity in the face of US funding cuts.

GBGMC Town Hall

Will Lenacapavir be a Lever or a Let-Down? Lessons, Resources and Considerations for Implementation in the United States

STIWatch Quarterly Newsletter

As many global health fields reassess their reliance on US government funding for research and development, the STI field—already underfunded and reliant on alternate donors—now faces even greater uncertainty. In this newsletter, we share a new STI resource for advocates and highlight the top issues we’re monitoring as events continue to unfold.

Key Takeaways from the STI & HIV 2025 World Congress

The STI & HIV World Congress brought together over 1,400 researchers, healthcare providers, advocates, funders and more in Montreal last week, where they shared urgent insights, promising innovations, and calls to action. The gathering came at a pivotal moment when rates of STIs are rising globally, amid massive disruptions caused by shifts in US policies and funding and decreased investments from other funders.

AVAC Condemns Administration’s Further Actions to Dismantle and Deconstruct U.S. Government Vaccine Research and Delivery Infrastructure

AVAC condemns a series of actions taken by the U.S. presidential administration to dismantle U.S. leadership in research, development and delivery of lifesaving vaccines. Without U.S. government leadership, the country and the world will remain woefully unprepared for ongoing and emerging pandemic threats.

AVAC Condemns Administration’s Further Actions to Dismantle and Deconstruct U.S. Government Vaccine Research and Delivery Infrastructure

AVAC condemns a series of actions taken by the U.S. presidential administration to dismantle U.S. leadership in research, development and delivery of lifesaving vaccines.

Global Health Watch: EMA recommends LEN, whistleblower report on foreign aid freeze, changes in NIH policies and new CDC director

Last Friday, the European Medicines Agency recommended injectable lenacapavir for PrEP. This comes amid more political chaos this week that threatens delivery including, a surprise funding freeze and its reversal, a new whistleblower report on the unlawful foreign aid freeze, changes in NIH policies and continued dismantling of federal advisory boards.

EXPrESSIVE Phase 3 Trials

Seventeen countries are hosting sites for Merck’s trials of a monthly pill for PrEP. Launch is expected in Q3 2025. This graphic shows where these trials are taking place.

What’s New & Next in HIV Prevention: Update on Research & Development AND Delivery